phospho-her4/erbb4 (tyr1284)/egfr (tyr1173) (21a9) #4757 antibody  (Cell Signaling Technology Inc)

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: The effects of ErbB4 receptor agonist E4A and melatonin on cognitive and spatial memory deficits in D-gal-induced aging mice. (A) Representative swimming trajectories of mice subjected to different treatments in the Morris Water Maze (MWM) spatial probe test. (B) Escape latency across the five experimental groups. (C) Number of target crossings during the MWM probe test. (D) Time spent in the target quadrant during the MWM probe test. (E) Representative heat map showing interaction frequency with novel versus familiar objects. (F) Recognition index in the Novel Object Recognition test among the experimental groups. (G) Spontaneous alternation behaviors in the Y-maze test were assessed. Data were presented as mean ± SD (n = 6–8). Statistical significance was denoted as follows: *p < 0.05, **p < 0.01, ****p < 0.0001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: Effect of ErbB4 receptor agonist and melatonin can ameliorate D-gal-induced aging in hippocampus in mice. (A) Western blot analysis of Lamin B1, p53, p21, p16, GFAP, and Iba-1 protein expression levels in the hippocampus of mice. (B–G) Quantification of Lamin B1, p53, p21, p16, GFAP, and Iba-1 protein levels. Data are presented as mean ± SD, with n = 4–5. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: Western Blot, Expressing

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: ErbB4 receptor agonist and melatonin inhibit ferroptosis in hippocampus in D-gal-induced aging mice. (A) Immunofluorescence analysis of GPX4-positive cells, SLC7A11-positive cells, TFRC-positive cells in the dentate gyrus (DG) and CA1 regions. Scale bar = 50 μm. (B) Western blot analysis of Nrf2, TFRC, SLC7A11, and GPX4 protein expression levels in the hippocampus of mice. (C–F) Quantification of Nrf2, TFRC, SLC7A11, and GPX4 protein levels. Data are presented as mean ± SD, with n = 4–5. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: Immunofluorescence, Western Blot, Expressing

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: The mitigation of D-gal-induced ferroptosis in HT22 cells by ErbB4 receptor agonist and melatonin. (A) Cell viability post D-gal exposure, evaluated using the CCK-8 assay (n = 5). (B) Cell viability following co-treatment with D-gal and ErbB4 receptor agonist, assessed via the CCK-8 assay (n = 6). (C) Cell viability following co-treatment with D-gal and melatonin, determined by the CCK-8 assay (n = 6). (D) Visualization of cellular senescence through SA-β-gal staining. Scale bar = 100 μm. (E) Quantification of SA-β-gal staining intensities (n = 3). (F) Western blot analysis was conducted to assess the expression levels of senescence-associated markers and ferroptosis-related proteins in HT22 cells. (G–M) Quantification of Nrf2, TFRC, SLC7A11, GPX4, p53, p21, and p16 levels was performed, with normalization to GAPDH (n = 4–7). (N) Intracellular GSH levels (n = 4). (O) Intracellular MDA levels (n = 5). (P) Quantitative analysis of ROS levels was undertaken (n = 4). (Q) Intracellular ROS generation was measured using DCFH-DA, wherein ROS activity was reflected as green fluorescence intensity. Scale bar = 200 μm. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: CCK-8 Assay, Staining, Western Blot, Expressing, Activity Assay, Fluorescence

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: The effects of ErbB4 receptor agonist and melatonin treatment on ferroptosis in Erastin-exposed HT22 cells. (A) Cell viability of HT22 cells post-Erastin exposure was evaluated using the CCK-8 assay (n = 5). (B) Cell viability was evaluated following treatment with Erastin, cotreatment with either E4A or melatonin, or both, utilizing the CCK-8 assay (n = 4). (C) Western blot analysis was conducted to determine the expression levels of senescence-associated markers and ferroptosis-related proteins in HT22 cells. (D–I) Quantitative analysis of Nrf2, TFRC, SLC7A11, GPX4, p21, and p16 levels, normalized to GAPDH (n = 4–7). (J) Intracellular ROS generation was measured using DCFH-DA, with ROS activity indicated by green fluorescence. Scale bar = 200 μm. (K) The quantitative analysis of ROS levels was conducted (n = 4). The data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: CCK-8 Assay, Western Blot, Expressing, Activity Assay, Fluorescence

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: ErbB4 receptor agonist mitigates D-gal-induced hippocampal neuronal aging both in vivo and in vitro through the activation of ErbB4 receptors and modulation of the Akt/Nrf2 signaling pathway. (A) Western blot analysis of pErbB4, ErbB4, pAkt1, and Akt1 protein expression levels in the hippocampus of mice. (B, C) Quantification of pErbB4 and pAkt1 levels (n = 4). (D) Western blot analysis of pErbB4, ErbB4, pAkt1, and Akt1 protein expression levels in D-gal-induced HT22 cells. (E, F) Quantification of pErbB4 and pAkt1 levels (n = 4). (G, H) Immunofluorescence analysis of the Nrf2-positive cells in the DG region (G) and in the cortex region (H) . Scale bar = 50 μm. (I) Western blot analysis of Nrf2, SLC7A11, GPX4, Lamin B1 and P21 protein levels after treatment of Nrf2 inhibitor AEM1. (J–N) Quantitative analysis of Nrf2, SLC7A11, GPX4, Lamin B1 and P21 levels (n = 4–7). Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: In Vivo, In Vitro, Activation Assay, Western Blot, Expressing, Immunofluorescence

Journal: Frontiers in Pharmacology

Article Title: Targeted ErbB4 receptor activation prevents D-galactose-induced neuronal senescence via inhibiting ferroptosis pathway

doi: 10.3389/fphar.2025.1528604

Figure Lengend Snippet: Schematic diagram illustrating the effects of targeted activation of ErbB4 receptor on neuronal aging via ferroptosis inhibition. Small molecule agonist (E4A)can activate ErbB4 receptors and regulate the Akt/Nrf2 signaling pathway to achieve neuroprotective effect in D-gal-induced neuronal aging. D-gal treatment increases the accumulation of advanced glycation end products (AGEs) which stimulates the production of reactive oxygen species (ROS) and increase the expression of senescence marker genes P53, P16, and P21. E4A can promote Akt1 phosphorylation and promote Nrf2 entrance into the nucleus, in which it involves in regulating the expression of ferroptosis suppressor gene, such as SLC7A11 and GPX4 to attenuate lipid peroxidation, which can inhibit cell ferroptosis and neuronal aging. The diagram was created with MedPeer ( www.medpeer.cn ).

Article Snippet: The antibodies used, diluted in primary antibody diluents (P0023A, Beyotime), included: rabbit anti-phospho-ErbB4 (bs-3220R, Bioss; 1:1,000), rabbit anti-ErbB4 (AF6807, Beyotime; 1:1,000), rabbit anti-phospho-Akt1 (AF1546, Beyotime; 1:1,000), mouse anti-Akt1 (sc-377457, Santa Cruz Biotech; 1:1,000), rabbit anti-Nrf2 (AF7623, Beyotime; 1:1,000), rabbit anti-TFRC (AF8136, Beyotime; 1:1,000), rabbit anti-SLC7A11 (GB115276, Servicebio Biotech; 1:1,000), rabbit anti-GPX4 (AF7020, Beyotime; 1:1,000), rabbit anti-Lamin B1 (12987-1-AP, Proteintech, 1:5,000), rabbit anti-p53 (AF5258, Beyotime; 1:1,000), mouse anti-p21 (AP021, Beyotime; 1:1,000), rabbit anti-p16 (bs-23797R, Bioss Biotech, Beijing, China; 1:1,000), and rabbit anti-GAPDH (GB15002, Servicebio Biotech; 1:2000).

Techniques: Activation Assay, Inhibition, Expressing, Marker

Journal: Cell Death Discovery

Article Title: Overexpressed nicotinamide N‑methyltransferase in endometrial stromal cells induced by macrophages and estradiol contributes to cell proliferation in endometriosis

doi: 10.1038/s41420-024-02229-3

Figure Lengend Snippet: A Differentially expressed genes downregulated in sh-NNMT-HESCs compared to sh-NC-HESCs and their enriched terms. B Western blot analysis comparing the protein expression of ERBB4, Y1056-phosphorylated ERBB4 (p-ERBB4), PI3K, phosphorylated PI3K (p-PI3K), AKT, phosphorylated AKT (p-AKT) in sh-NNMT-HESCs to sh-NC-HESCs and the blank control, with β-ACTIN as the loading control. C Impact of ERBB4 overexpression on the protein expression of ERBB4, p-ERBB4, PI3K, p-PI3K, AKT, p-AKT in sh-NNMT-HESCs and sh-NC-HESCs. ERBB4, erb-b2 receptor tyrosine kinase 4. PI3K, phosphatidylinositol 3-kinase. D CCK-8 assay evaluating the effect of ERBB4 overexpression on the proliferation capacity of sh-NNMT-HESCs ( n = 3). Data are presented as the mean ± SEM and analyzed using two-way ANOVA with Tukey’s post hoc test. ns, not significant. ** p < 0.01. **** p < 0.0001.

Article Snippet: The membranes were blocked with 5% skim milk or bovine serum albumin for one hour at room temperature and then incubated with primary rabbit antibodies against NNMT (ab119758, Abcam, Cambridge, UK), VINCULIN (#13901, Cell Signaling Technology, MA, USA), α-TUBULIN (ab52866, Abcam, UK), β-ACTIN (AF7018, Affinity Biosciences, Jiangsu, China), ERBB4 (AF6445, Affinity Biosciences, USA), phospho-ERBB4 (AF8370, Affinity Biosciences, USA), PI3K (A23303, ABclonal, Wuhan, China), phospho-PI3K (AP0854, ABclonal, China), AKT (#4691T, Cell Signaling Technology, USA), and phospho-AKT (#4058T, Cell Signaling Technology, USA) at 4 °C overnight.

Techniques: Western Blot, Expressing, Control, Over Expression, CCK-8 Assay

Journal: Food Science & Nutrition

Article Title: Isothiocyanates attenuate heparin‐induced proliferation of colon cancer cells in vitro

doi: 10.1002/fsn3.4296

Figure Lengend Snippet: (a) Illustrative images depicting the expression levels of ErbB1, ErbB2, ErbB4, and β ‐actin. (b) Levels of ErbB1, ErbB2, and ErbB4 normalized to β ‐actin. (c) Gene expression levels of ErbB1, ErbB2, and ErbB4 measured by qPCR. Data are presented as mean ± SD ( n ≥ 3). # p < .1, ## p < .1, and #### p < .0001 compared with the control group, * p < .1, ** p < .01, *** p < .001, and **** p < .0001 compared with the heparin group.

Article Snippet: Protein bands were then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, USA) and blocked with 5% nonfat milk in TBST (Tris‐buffered saline containing 0.1% Tween 20) at room temperature for 2 h. The membranes were incubated overnight with primary antibodies at 4°C targeting TGF‐ β (CST, 3709S), EGFR (ErbB1) (epidermal growth factor receptor) (CST, 4267T), HER2 (ErbB2) (receptor tyrosine‐protein kinase erbB‐2) (CST, 4290T), HER3 (ErbB3) (receptor tyrosine‐protein kinase erbB‐3) (CST, 12708T), HER4 (ErbB4) (receptor tyrosine‐protein kinase erbB‐4) (CST, 4795T), Bcl‐2 (B‐cell lymphoma 2) (CST, 3498T), Bax (Bcl‐2‐associated X protein) (CST, 2772T), and β ‐actin (CST, 8457T).

Techniques: Expressing, Gene Expression, Control

Journal: World Journal of Oncology

Article Title: Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells

doi: 10.14740/wjon1873

Figure Lengend Snippet: Surface Expression of Various Growth Factor Receptors in Human Brain Cancer Cell Line (Determined by Flow Cytometry)

Article Snippet: Other antibodies for the Western blot analysis, such as the rabbit anti-phospho-EGFR (Tyr1068), HER2 (2242s), phosphor-HER2 (Tyr1221/1222) (2243), phosphor-HER3 (Tyr1289) (4791), phosphor-HER4 (Tyr1284)/EGFR (Tyr1173) (4757), phosphor-MAPK (Tyr202/Tyr204) (4370), phospho-Akt (S473) (4060), phospho-STAT3 (Y705) (9145), phospho-SRC (Y416) (Tyr416) (6942) and β-actin (4970), were all obtained from Cell Signaling Technology Inc. (Hitchin, UK).

Techniques: Expressing, Cytometry, Fluorescence

Journal: World Journal of Oncology

Article Title: Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells

doi: 10.14740/wjon1873

Figure Lengend Snippet: IC 50 Values of Various Agents on HBCCLs as Assessed by SRB Colorimetric Assay: (A) HER-Family Targeting TKIs and Other Downstream Signaling Molecules and (B) Other TKIs and Chemotherapeutic Agents

Article Snippet: Other antibodies for the Western blot analysis, such as the rabbit anti-phospho-EGFR (Tyr1068), HER2 (2242s), phosphor-HER2 (Tyr1221/1222) (2243), phosphor-HER3 (Tyr1289) (4791), phosphor-HER4 (Tyr1284)/EGFR (Tyr1173) (4757), phosphor-MAPK (Tyr202/Tyr204) (4370), phospho-Akt (S473) (4060), phospho-STAT3 (Y705) (9145), phospho-SRC (Y416) (Tyr416) (6942) and β-actin (4970), were all obtained from Cell Signaling Technology Inc. (Hitchin, UK).

Techniques: Colorimetric Assay, Polymer